RCT | Single-dose psilocybin-assisted therapy in major depressive disorder

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial – eClinicalMedicine

Commentary: A single, moderate dose of psilocybin reduces depressive symptoms for at least two weeks, controlled study finds – PsyPost

Related:

Phase 2 RCT | Single-dose Psilocybin for a treatment-resistant episode of major depression.

RCT | In patients with alcohol use disorder, the percentage of heavy drinking days was reduced with a psychedelic drug.

Phase 2 RCT: Psilocybin, a psychedelic compound, shows promise for the treatment of depression in a study with 59 patients

Research: “Magic mushrooms” for treatment-resistant depression

Commentary on Twitter

?New placebo-controlled, double-blind, RCT: Single-dose #psilocybin-assisted therapy in #majordepressivedisorder

Results suggest that a single dose of psilocybin significantly reduces depressive symptoms compared to placebo for at least 2 weekshttps://t.co/Ps43rxHv6r pic.twitter.com/Qc8xSgnalw

— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) January 18, 2023